Tianjin Lisheng Pharmaceutical Co.,Ltd. Stock

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-27 pm EDT 5-day change 1st Jan Change
17.55 CNY -4.14% Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. -5.43% -5.86%
Sales 2022 1.15B 158M Sales 2023 1.15B 159M Capitalization 4.81B 664M
Net income 2022 93M 12.84M Net income 2023 362M 49.97M EV / Sales 2022 1.72 x
Net cash position 2022 1.95B 269M Net cash position 2023 2.19B 302M EV / Sales 2023 2.27 x
P/E ratio 2022
41.7 x
P/E ratio 2023
13.2 x
Employees 1,328
Yield 2022
1.41%
Yield 2023
2.3%
Free-Float 44.72%
More Fundamentals * Assessed data
Dynamic Chart
Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 28 May 2024 CI
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4% MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lisheng Pharmaceutical Buys 65% Stake in Qingchun Kangyuan Pharmaceutical for 137 Million Yuan; Shares Up 3% MT
Tianjin Arm Lisheng Pharmaceutical To Buy Chinese Medicine Firm Jiangxi Qingchun Kangyuan MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million. CI
Tianjin Lisheng Pharma Setting Up Venture Capital Fund MT
Lisheng Pharmaceutical and Lisheng Investment Enter into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway CI
Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million. CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day-4.14%
1 week-5.43%
Current month-3.46%
1 month-1.44%
3 months+5.91%
6 months-10.49%
Current year-5.86%
More quotes
1 week
17.41
Extreme 17.41
18.96
1 month
17.41
Extreme 17.41
19.39
Current year
12.61
Extreme 12.6142
19.61
1 year
12.61
Extreme 12.6142
20.57
3 years
12.61
Extreme 12.6142
20.57
5 years
11.76
Extreme 11.757
21.42
10 years
11.76
Extreme 11.757
42.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 17-11-14
Director of Finance/CFO 41 -
Investor Relations Contact - -
Members of the board TitleAgeSince
Chairman 55 22-11-02
Chief Executive Officer 57 17-11-14
Director/Board Member 54 20-12-27
More insiders
Date Price Change Volume
24-05-27 17.55 -4.14% 2 397 429
24-05-27 18.31 +0.16% 2,069,685
24-05-24 18.28 +0.16% 1,985,246
24-05-23 18.25 -3.37% 3,434,227
24-05-22 18.89 +1.50% 2,861,058

End-of-day quote Shenzhen S.E., May 27, 2024

More quotes
Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.
More about the company
  1. Stock Market
  2. Equities
  3. 002393 Stock